Abu Dhabi Health Department Signs MoU with Xlife Sciences to Boost Life-Sciences Sector

By Staff Writer

September 12, 2023

The Department of Health – Abu Dhabi (DoH) and Swiss firm Xlife Sciences have signed a Memorandum of Understanding (MoU) in a bid to fortify the Emirate’s life-sciences sector. The agreement, which was signed at the Department’s Headquarters, aims to enhance innovation, funding opportunities for life sciences start-ups, and clinical research within the Emirate.

The collaboration is part of DoH’s ongoing efforts to establish Abu Dhabi as a global hub for healthcare and life sciences. It will provide incubation training, mentoring, and commercialisation support to innovators, while also exploring the possibility of a joint funding framework with local ecosystem partners.

Dr. Asma Ibrahim Al Mannaei, Executive Director of Research and Innovation Centre at the DoH, expressed her delight at the collaboration, citing it as a step towards addressing global healthcare challenges and reinforcing the development of Abu Dhabi’s life sciences sector.

Xlife Sciences, represented by CEO Oliver R. Baumann, has established their UAE presence through a partnership with ICEBERG Capital, a company based in Abu Dhabi Global Market (ADGM) and regulated by Financial Services Regulatory Authority (FSRA). ICEBERG Capital will be handling the company’s investment strategy and fund management, further enhancing the life sciences ecosystem in Abu Dhabi.

Abdullah Al Weshah, Managing Director – ICEBERG Capital, commented on the collaboration, expressing excitement at the prospect of supporting the Abu Dhabi Life-Sciences ecosystem and looking forward to establishing a joint funding framework to support start-ups, founders, and projects.

This agreement further cements Abu Dhabi’s position as a global life sciences hub and an incubator for healthcare innovation, while spearheading the transformation of the regional healthcare ecosystem through leveraging sciences and technology. 

Reference url

Recent Posts

Thimerosal Vaccine Removal: HHS Finalizes Decision

By Staff Writer

July 24, 2025

The U.S. Department of Health and Human Services (HHS) has finalized its decision to remove thimerosal from influenza vaccines. This follows a 2025 CDC committee vote to limit thimerosal to single-dose, mercury-free formulations for children, pregnant women, and adults. HHS Secretary Robert F. Ke...
Facilitators and Barriers in AI Medical Imaging Implementation: A Systematic Review

By Staff Writer

July 22, 2025

What are the main AI medical imaging barriers and how do they impact real-world integration in healthcare? Successfully adopting AI in routine medical imaging requires overcoming a complex set of obstacles while leveraging facilitators to streamline the process. A recently published in-depth r...
Model Type and Its Impact on Pneumococcal Vaccine Cost-Effectiveness in Germany

By João L. Carapinha

July 21, 2025

This update critically evaluates the article “Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany.” It explores the pneumococcal vaccine cost-effectiveness through two distinct mode...